GENSCRIPT BIO(HK:01548)2025-08-17 23:15Financial Performance - The Group's revenue from continuing operations reached $518.8 million, marking an impressive 81.9% year-over-year increase compared to H1 2024[5,65] - Adjusted net profit from continuing operations soared to $178.0 million, a substantial 509.6% increase compared to the $29.2 million in H1 2024[5,65] - GenScript revenue increased by 11.3% to $247.6 million[65,67] - ProBio experienced significant growth, with revenue reaching $246.9 million, a 511.1% increase[5,65,70] - Bestzyme's revenue grew by 8.4% to $28.3 million[65,73] GenScript Highlights - GenScript served over 42,000 customers in H1 2025, up from 39,000+ in H1 2024[18] - The number of scientific journals citing GenScript increased to over 112,000, compared to 100,000+ in H1 2024[18] - R&D functions account for approximately 10% of the 5700+ employees globally[6] ProBio Highlights - ProBio's cash position is $371.1 million[70] - 20 CDMO projects in H1 2025, with >50% from global customers[42] Bestzyme Highlights - Bestzyme's R&D expenses increased by 62%, from $2.9 million in H1 2024 to $4.7 million in H1 2025[59] - International revenue contribution increased, accounting for 23% of revenue in H1 2025 compared to 21% in H1 2024[73] Guidance - The company revised its revenue growth target for FY 2025 from 10%-15% to 13%-15%[78] - Bestzyme expects 20%-25% revenue growth with Adjusted GPM ~45%[78]